- Home
- FORA vs INMB Comparison
FORA vs INMB Comparison
Compare FORA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- INMB
- Stock Information
- Founded
- FORA 2014
- INMB 2015
- Country
- FORA United States
- INMB United States
- Employees
- FORA N/A
- INMB N/A
- Industry
- FORA Computer Software: Prepackaged Software
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- INMB Health Care
- Exchange
- FORA Nasdaq
- INMB Nasdaq
- Market Cap
- FORA 60.2M
- INMB 68.9M
- IPO Year
- FORA N/A
- INMB 2019
- Fundamental
- Price
- FORA $2.21
- INMB $2.24
- Analyst Decision
- FORA Strong Buy
- INMB Buy
- Analyst Count
- FORA 1
- INMB 4
- Target Price
- FORA $5.00
- INMB $9.53
- AVG Volume (30 Days)
- FORA 52.6K
- INMB 2.2M
- Earning Date
- FORA 08-13-2025
- INMB 08-07-2025
- Dividend Yield
- FORA N/A
- INMB N/A
- EPS Growth
- FORA N/A
- INMB N/A
- EPS
- FORA N/A
- INMB N/A
- Revenue
- FORA $25,031,040.00
- INMB $50,000.00
- Revenue This Year
- FORA $47.82
- INMB $142.83
- Revenue Next Year
- FORA $10.11
- INMB $14,780.90
- P/E Ratio
- FORA N/A
- INMB N/A
- Revenue Growth
- FORA 18.59
- INMB N/A
- 52 Week Low
- FORA $1.64
- INMB $1.89
- 52 Week High
- FORA $4.03
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- FORA 65.42
- INMB 36.94
- Support Level
- FORA $1.64
- INMB $2.32
- Resistance Level
- FORA $2.04
- INMB $2.44
- Average True Range (ATR)
- FORA 0.13
- INMB 0.15
- MACD
- FORA 0.01
- INMB 0.05
- Stochastic Oscillator
- FORA 53.27
- INMB 4.69
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.